Application of a polypeptide as an olfactory receptor olfr109 antagonist ligand

Abstract

The disclosure belongs to the technical field of anti-metabolic disease drugs, and in particular relates to the application of a polypeptide as an olfactory receptor Olrfr109 antagonist ligand. Existing studies have shown that the olfactory receptor Olfr109 plays an important role in maintaining blood glucose homeostasis and also affects insulin secretion levels. Based on this research background, the present disclosure provides an antagonist ligand for the olfactory receptor Olfr109, the polypeptide can inhibit downstream Gi, β-arrestin1 and β-arrestin2 signaling pathways by binding to Olfr109, and can be used to prepare metabolic diseases As a model drug, the function of the antagonist is to alleviate the insulin secretion disorder caused by the overactivation of Olfr109, and promote insulin secretion. As a good clinical drug or research tool, it has promotional significance.

Description

technical field [0001] The disclosure belongs to the technical field of anti-metabolic disease drugs, and specifically relates to the application of a polypeptide as an olfactory receptor Olfr109 antagonist ligand and Gi, β-arrestin-1 and β-arrestin-2 signal pathway inhibitors. Background technique [0002] The information disclosed in this Background section is only intended to increase the understanding of the general background of the disclosure, and is not necessarily to be taken as an acknowledgment or any form of suggestion that the information constitutes prior art that is already known to those skilled in the art. [0003] Diabetes mellitus is a metabolic disease characterized by elevated blood sugar. Insufficient insulin secretion or insulin resistance is a key factor in the occurrence of diabetes. Currently commonly used hypoglycemic drugs in clinical practice, such as biguanides, thiazolidinediones, and sulfonylureas, have significant short-term efficacy, but long...

AI Technical Summary

Problems solved by technology

At present, commonly used hypoglycemic drugs in clinic, such as biguanides, thiazolidinediones and sulfonylureas, etc., although the short-term efficacy is significant, but long-term use is usually accompanied by a variety of side effects, such as gastrointestinal discomfort and osteoporosis, etc.

Images